anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine gel plaster applied to acupoints to treat insomnia. The gel plaster comprises a back lining layer, an ointment layer and a cover lining layer. The ointment layer comprises medicine extract, framework material, sticking agent, humectant, filler, crosslinking agent, crosslinking modifier and transdermal enhancer. The medicine extract is prepared by extracting prepared radix astragali, radix codonopsis, angelica sinensis, rhizoma chuanxiong, semen platycladi, semen ziziphi spinosae, polygala tenuifolia (prepared), Chinese magnoliavine fruit (steamed), cinnamon, poria cocos, fermented pinellia, cinnabar and prepared liquorice. A preparation method of the traditional Chinese medicine gel plaster sequentially includes: preparing the medicine extract, preparing matrix, and preparing the gel plaster. By the traditional Chinese medicine gel plaster, insomnia can be treated effectively while adverse effect of intoxication caused by the fact that toxic components produced by orally taking preparation containing the cinnabar accumulate in the bodies of patients can be avoided.
BACKGROUND: Little real-world experience regarding the use of baricitinib, an oral selective JAK1/JAK2 inhibitor, for treating moderate to severe atopic dermatitis (AD) has been reported.
METHODS: This study aimed to assess the overall outcomes in Korean patients with AD treated with baricitinib. All patients with moderate to severe AD treated with baricitinib between June 2021 and June 2022 were included, and their cases were retrospectively analyzed using medical records. Patients with moderate to severe AD, aged ≥18 years who had failed previous therapies, including those who demonstrated unsatisfactory improvement with dupilumab, were prescribed baricitinib. Patients whose follow-up period was <8 weeks were excluded. The dermatologist evaluated the AD status, including eczema area and severity index (EASI), itch Numeric Rating Scale, and improvement of remaining lesions despite dupilumab therapy.
RESULTS: We analyzed 34 AD patients who received baricitinib. Twelve patients treated with dupilumab were additionally prescribed baricitinib due to unsatisfactory treatment effects and demonstrated improvement in the remaining lesions despite dupilumab treatment. Their itching improved after 1.4 weeks. Among them, eight patients (66.7%) had head and neck dermatitis, and seven of them demonstrated improvement after the coadministration of baricitinib. Among the other 22 patients who were prescribed baricitinib only, 10 patients (45.5%) achieved EASI 75 at 8 weeks, with five (22.7%) revealing EASI 90.
CONCLUSIONS: Overall, baricitinib was well tolerated and resulted in clinical improvement in AD patients in a real-world clinical setting. Additionally, baricitinib may be beneficial in treating lesions refractory to dupilumab therapy.
Title cpds. are of formula: (where R is 19-30C alkyl). Prepn. is e.g. by esterification of 5-pyrrolidone-2-COOH or its halide or anhydride with R.OH in the presence of a strong acid or an acid-activating substance e.g. SOCl2 or N, N1-dicyclohexylcarbodiimi de. The title esters, specif. the nonadecyl ester, are therapeutic and cosmetic agents for skin care and treatment exerting an inhibition of sebum glands and an anti-inflammatory action.
PROBLEM TO BE SOLVED: To obtain a dermal preparation for external use excellent in humectancy and good in stability over a passage of time, containing urea and a dipeptide and/or tripeptide as active ingredient. SOLUTION: This dermal preparation for external use contains, as active ingredients, (A) 0.01-20wt.% of urea and (B) a dipeptide and/or tripeptide at the weight ratio A/B of 1:(0.1-1). The constitutive amino acids of the component B are pref. selected from glycine, alanine, arginine, lysine, cysteine, aspartic acid and/or its salts and glutamic acid and/or its salts. The dermal preparation is made into skin care products, makeup products, hair care products, etc., by formulating the active ingredients appropriately with a surfactant, lubricant, powder, water-soluble polymer, moisturizing agent, cosmetic ingredient(s), medicinal agent, ultraviolet light absorber, dye, perfume, etc. The dermal preparation for external use is formulated with the urea stably, is suppressed in pH change and in generation of ammonia odor.
As with all therapeutic proteins, there is a potential for immunogenicity to EMPLICITI. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to EMPLICITI in the studies described below with the incidences of antibodies in other studies or to other products may be misleading.

Of 390 patients across four clinical studies including ELOQUENT-2 and in 53 patients in the ELOQUENT-3 trial, who were treated with EMPLICITI and evaluable for the presence of anti-product antibodies, 72 patients (18.5%) in the four clinical trials and 19 patients (36%) in the ELOQUENT-3 trial tested positive for treatment-emergent anti-product antibodies by an electrochemiluminescent (ECL) assay. In 63 (88%) of the 72 patients in the four clinical trials, anti-product antibodies occurred within the first 2 months of the initiation of EMPLICITI treatment and resolved by 2 to 4 months in 49 (78%) patients. In the ELOQUENT-3 trial, in all 19 patients, anti-product antibodies occurred within the first 2 months of the initiation of EMPLICITI treatment and were resolved by 2 to 3 months in 18 (95%) patients.

Neutralizing antibodies post-treatment were detected in 19 of 299 patients in the four clinical trials and 2 of 53 patients in the ELOQUENT-3 trial who were evaluable for the presence of neutralizing antibodies.
The aim of the study is to examine the role of HLA and killer immunolobulin-like receptors (KIR) in the natural history of HPV, HCV, and HBV in HIV-positive and HIV-negative women. The immune response to viral infection mediated by T lymphocytes is HLA restricted, suggesting that HLA class I, and class II might be associated with risk of viral infection, persistence and disease progression. Natural killer (NK) cells are a unique group of lymphocytes involved in surveillance and killing of foreign or infected cells through a mechanism involving recognition of HLA molecules by an extremely diverse set of receptors on the NK cell surface. A major group of these receptors are the KIRs. Thus, a relationship between KIR genotype and HIV infection is biologically plausible, and requires further investigation in observational studies.

The WIHS study is a prospective study, which may allow us to answer questions relating to the role of host HLA and KIR genotype on duration of infection, and the development of virus-associated diseases such as cervical cancer (related to HPV infection), and liver cancer (HBV and HCV). WIHS is a large, racially and geographically diverse cohort of HIV positive (n = 2761), and risk-matched HIV-negative women (n = 942). The large size of the cohort will provide substantial statistical power, which is of major importance in any HLA association study.
Cardiac fibrosis is a detrimental pathological process, which constitutes the key factor for adverse cardiac structural remodeling leading to heart failure and other critical conditions. Circular RNAs (circRNAs) have emerged as important regulators of various cardiovascular diseases. It is known that several circRNAs regulate gene expression and pathological processes by binding miRNAs. In this study we investigated whether a novel circRNA, named circNSD1, and miR-429-3p formed an axis that controls cardiac fibrosis. We established a mouse model of myocardial infarction (MI) for in vivo studies and a cellular model of cardiac fibrogenesis in primary cultured mouse cardiac fibroblasts treated with TGF-β1. We showed that miR-429-3p was markedly downregulated in the cardiac fibrosis models. Through gain- and loss-of-function studies we confirmed miR-429-3p as a negative regulator of cardiac fibrosis. In searching for the upstream regulator of miR-429-3p, we identified circNSD1 that we subsequently demonstrated as an endogenous sponge of miR-429-3p. In MI mice, knockdown of circNSD1 alleviated cardiac fibrosis. Moreover, silence of human circNSD1 suppressed the proliferation and collagen production in human cardiac fibroblasts in vitro. We revealed that circNSD1 directly bound miR-429-3p, thereby upregulating SULF1 expression and activating the Wnt/β-catenin pathway. Collectively, circNSD1 may be a novel target for the treatment of cardiac fibrosis and associated cardiac disease.
PURPOSE:To enable to freely obtain Atropine and scopolamine in an industrial level by deriving callus in Duboisia plant, culturing it by serial passage and extracting solvent medium. CONSTITUTION:Components such as leaves and stems of Duboisia plant are used as mother plant, which is cut into pieces of squares having 5mm. side, and the pieces are placed and cultured on agar-agar medium in a flask. The pieces are steadily placed and cultured in a contant-temperature chamber of 25 deg.C for a period longer than one month to obtain callus stump, which is further cultured by serial passage in the same medium as that at the deriving time of the callus for two months, is then frozen, dried to obtain extracted raw material. The extracted solution is then concentrated. The concentrate is then dissolved in chloroform, in analyzed by a gas chromatography, thereby obtaining Atropine and scopolamine.
This study examined the genotype, allelic frequencies (polymorphisms) in a sample of Egyptian patients and examined the relationship between disease activity in systemic lupus erythematosus (SLE) and the B lymphoid tyrosine kinase (BLK) and B-cell scaffold protein with ankyrin repeats 1 (BANK1) gene. This case control study involved 70 SLE patients and 40 subjects matched for age and sex as a control group. Clinical data were gathered from each participant, including SLE-related clinical activity indicators. Utilizing the restriction fragment length polymorphism (RFLP)-polymerase chain reaction (PCR), the single nucleotide polymorphisms (SNPs) BLK rs13277113G/A and BANK1 rs10516487G/A were assessed. The most prevalent genotype among the study participants was BLK rs13277113; G/G (57.1%), and BANK rs10516487; GG/ genotype (74.3%). There were no substantial variations in the incidence of genotype and allelic polymorphism between patients and controls (p>0.05). In the studied SLE patients, however, there was no significant association between both alleles (BANK rs10516487 gene alleles, G/G and G/A and BLK rs13277113, G/A, G/G and A/A) and the SLE disease activity score. While there was a significant association between BLK rs13277113 genotype alleles and age. In conclusion, BLK rs13277113 G/A and BANK1 rs10516487 G/A alleles showed no difference between SLE Egyptian patients compared to controls with no link between both genes and SLE disease activity.
Tobramycin for Injection, USP may be given intramuscularly or intravenously. Recommended dosages are the same for both routes. This insert is for a Pharmacy Bulk Package and is intended for preparing I.V. admixtures only. Dosage recommendations for intramuscular use are for informational purposes only. The patient’s pretreatment body weight should be obtained for calculation of correct dosage. It is desirable to measure both peak and trough serum concentrations (see WARNINGS box and PRECAUTIONS).
In the presence of a high environmental temperature, heat prostration can occur with drug use (fever and heat stroke due to decreased sweating). If symptoms occur, the drug should be discontinued and supportive measures instituted. 

Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance, treatment with this drug would be inappropriate and possibly harmful. 

Dicyclomine hydrochloride may produce drowsiness or blurred vision. The patient should be warned not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery or performing hazardous work while taking this drug. 

Psychosis has been reported in sensitive individuals given anticholinergic drugs. CNS signs and symptoms include confusion, disorientation, short-term memory loss, hallucinations, dysarthria, ataxia, coma, euphoria, decreased anxiety, fatigue, insomnia, agitation and mannerisms, and inappropriate affect. 

These CNS signs and symptoms usually resolve within 12 to 24 hours after discontinuation of the drug. 

There are reports that administration of dicyclomine hydrochloride syrup to infants has been followed by serious respiratory symptoms (dyspnea, shortness of breath, breathlessness, respiratory collapse, apnea, asphyxia), seizures, syncope, pulse rate fluctuations, muscular hypotonia, and coma. Death has been reported. No causal relationship between these effects observed in infants and dicyclomine administration has been established. DICYCLOMINE IS CONTRAINDICATED IN INFANTS LESS THAN 6 MONTHS OF AGE AND IN NURSING MOTHERS. (See CONTRAINDICATIONS and PRECAUTIONS: Nursing Mothers and Pediatric Use). 

Safety and efficacy of dicyclomine hydrochloride in pediatric patients have not been established.
The invention discloses application of LncRNA-ENST00000581911 in preparing a thyroid-related eye disease (TAO) diagnostic reagent. The lncRNA-ENST00000581911 was found to exhibit significant correlation with TAO generation by high throughput sequencing and quantitative PCR validation and could be used for screening of clinical TAO patients. The invention also provides a lncRNA-ENST00000581911 kit for TAO diagnosis. The kit mainly comprises an RNA extraction system, a reverse transcription reaction system and a PCR reaction system. The relative expression level of lncRNA-ENST00000581911 in extraocular muscles is detected by a real-time fluorescence quantitative PCR technology and is used for early diagnosis of TAO. The method has the characteristics of small traumability, high sensitivity and simple operation.
Standard of Care as wait list control. Control group will be offered intervention as part of usual clinical care at 6 months.
Participants are experienced two phases of our study. The first phase, participants are received auricular acupuncture at TF4, AT4, LO1, LO3 points in the left ear. The second phase, participants are received sham acupuncture at the same points. The facial pain threshold will be recorded before and after performing auricular acupuncture.
PURPOSE:To obtain the titled high-purity compound useful as a transformation inhibitor for cells, etc., by reacting myristic acid chloride with glycine, etc., in the presence of an alkali in an inert polar solvent or an aqueous solution containing the inert polar solvent. CONSTITUTION:Myristic acid chloride is reacted with glycine or NH2-end glycine oligopeptide in the presence of an alkali (e.g. NaHCO3, Na2CO3, NaOH, Na3PO4, etc.) in an inert polar solvent (e.g. scetonitrile, acetone, methyl ethyl ketone, etc.) or an aqueous solution containing the solvent to give myristylglycine or an oligopeptide derivative thereof. Existence of the polar solvent in the reaction system provides the aimed effective substance. The amount of the polar solvent added is preferably about 10-70wt%, more preferably 20-50wt% based on water.
Hair treating formulation comprises pref. equal amts. of almonds, neem tree seed kernels and mighazkadro seeds. Pref. the components are finely ground together and mixed with water to form a paste which is spread on the scalp and left for 2-3 hrs., or vernight, then washed off. Compsn. prevents hair loss and increases growth when the roots have not died. Treatment may be daily or 1-2 times per week. Compsn. also prevents dandruff, cures diseases or irritation of the eyes, ears and facial skin resulting from dandruff. In an example a balding male (35) used the compsn. overnight 2-3 times per week for 4 months to restore hair growth and give a full head of hair.
The invention belongs to the field of a pharmaceutical preparation, and particularly relates to a mixed carbohydrate-electrolyte injection and a preparation method thereof. A pH modifier of the injection is citric acid, and pH is 4.0-4.4. By controlling the dosage range of the pH modifier, the pH range of the finished product can meet the specification only by regulating the pH value for one time in the preparation process. In addition, according to the method, activated carbon is added only in the step, and the activated carbon is not added in the preparation process, so that the risk of introducing metal ions and other impurities through the activated carbon can be effectively avoided, and toxins in bacteria of the finished product are qualified. According to the method, the technology is further simplified, the production time and cost can be shortened and lowered, and the sterilized product has no crystallization or precipitation phenomenon. After being stored for 24 months, the 5-hydroxymethyl-furfural range of the injection is within 0.03-0.05, and the impurities are controlled at the extremely low level; after being stored for 24 months, the injection almost has no character change and is still colorless clear liquid compared with the injection which is stored for zero day.
BACKGROUND: Cardiac hypertrophy is characterized by remodeling of the myocardium, which involves alterations in the ECM (extracellular matrix) and cardiomyocyte structure. These alterations critically contribute to impaired contractility and relaxation, ultimately leading to heart failure. Emerging evidence implicates that extracellular signaling molecules are critically involved in the pathogenesis of cardiac hypertrophy and remodeling. The immunophilin CyPA (cyclophilin A) has been identified as a potential culprit. In this study, we aimed to unravel the interplay between eCyPA (extracellular CyPA) and myocardial dysfunction and evaluate the therapeutic potential of inhibiting its extracellular accumulation to improve heart function.
METHODS: Employing a multidisciplinary approach encompassing in silico, in vitro, in vivo, and ex vivo experiments we studied a mouse model of cardiac hypertrophy and human heart specimen to decipher the interaction of CyPA and the cardiac microenvironment in highly relevant pre-/clinical settings. Myocardial expression of CyPA (immunohistology) and the inflammatory transcriptome (NanoString) was analyzed in human cardiac tissue derived from patients with nonischemic, noninflammatory congestive heart failure (n=187). These analyses were paralleled by a mouse model of Ang (angiotensin) II-induced heart failure, which was assessed by functional (echocardiography), structural (immunohistology, atomic force microscopy), and biomolecular (Raman spectroscopy) analyses. The effect of inhibiting eCyPA in the cardiac microenvironment was evaluated using a newly developed neutralizing anti-eCyPA monoclonal antibody.
RESULTS: We observed a significant accumulation of eCyPA in both human and murine-failing hearts. Importantly, higher eCyPA expression was associated with poor clinical outcomes in patients (P=0.043) and contractile dysfunction in mice (Pearson correlation coefficient, -0.73). Further, myocardial expression of eCyPA was critically associated with an increase in myocardial hypertrophy, inflammation, fibrosis, stiffness, and cardiac dysfunction in vivo. Antibody-based inhibition of eCyPA prevented (Ang II)-induced myocardial remodeling and dysfunction in mice.
CONCLUSIONS: Our study provides strong evidence of the pathogenic role of eCyPA in remodeling, myocardial stiffening, and dysfunction in heart failure. The findings suggest that antibody-based inhibition of eCyPA may offer a novel therapeutic strategy for nonischemic heart failure. Further research is needed to evaluate the translational potential of these interventions in human patients with cardiac hypertrophy.
VAY736 + lenalidomide dose expansion in patients with DLBCL. This arm will not be conducted.
The present disclosure provides a substance for treatment and/or prevention of diseases, the method for designing the substance, and the method for preparing the substance. A stable structure corresponding to a substance associated with diseases is used as the substance for treatment or prevention of the diseases. The essence of disease is the imbalance of the biological structure system. The structural imbalance of different substances will cause different diseases. The present invention discloses that the biological body recognizes the stable structure corresponding to the substance, adjusts its gene or gene expression by the self-adaptation and self-organization functions of its own structural system, and restores the biological structure system to be related to the substance. The balance of structure, treatment and/or prevention of diseases related to the substance.
Participants will engage in a live zoom exercise session. Participants will undergo 45 minutes of aerobic exercise intervention, three times a week, for a period of 12 weeks. Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
Oral dapsone treatment has produced dose-related hemolysis and hemolytic anemia. Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency are more prone to hemolysis with the use of certain drugs. G6PD deficiency is most prevalent in populations of African, South Asian, Middle Eastern, and Mediterranean ancestry. 

Some subjects with G6PD deficiency using dapsone gel, 5% developed laboratory changes suggestive of hemolysis. There was no evidence of clinically relevant hemolysis or anemia in patients treated with dapsone gel, 5%, including patients who were G6PD deficient. 

Discontinue dapsone gel, 5%, if signs and symptoms suggestive of hemolytic anemia occur. Avoid use of dapsone gel, 5% in patients who are taking oral dapsone or antimalarial medications because of the potential for hemolytic reactions. Combination of dapsone gel, 5%, with trimethoprim/sulfamethoxazole (TMP/SMX) may increase the likelihood of hemolysis in patients with G6PD deficiency.
All subjects will have two sets (left and right) of 4 semi-occlusive test patches applied to randomized test sites on their upper backs on Day 1. Test patches on left back will be for simple-patch test and those on right back will be for photo-patch test. Each set will consist of approximately 150 micro liter (0.15 mL) of the following study treatments: GSK2894512 0.5% cream, GSK2894512 1% cream, placebo (cream vehicle without the active ingredient) and an empty patch. The test patches will be applied for 24 hrs (photo-patch test) or 48 hrs (simple-patch test).